Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;74(1):530.
doi: 10.1002/hep.31667. Epub 2021 Apr 27.

Letter to the Editor: ABIDE in NAFLD: A Potential Game Changer in a Select Cohort of Cirrhosis

Amarjit Keisham  1 , Sunil Taneja  1 , Akash Roy  1 , Virendra Singh  1
Affiliations
Comment

Letter to the Editor: ABIDE in NAFLD: A Potential Game Changer in a Select Cohort of Cirrhosis

Amarjit Keisham et al. Hepatology. 2021 Jul.
No abstract available

PubMed Disclaimer

Comment in

  • REPLY.
    Calzadilla-Bertot L, Vilar-Gomez E, George J, Adams LA. Calzadilla-Bertot L, et al. Hepatology. 2021 Jul;74(1):531-532. doi: 10.1002/hep.31666. Epub 2021 Jun 15. Hepatology. 2021. PMID: 33277720 No abstract available.

Comment on

References

    1. Calzadilla-Bertot L, Vilar-Gomez E, Wong VW, Romero-Gomez M, Aller-de la Fuente R, Wong GL, et al. ABIDE: an accurate predictive model of liver decompensation in patients with non-alcoholic fatty liver-related cirrhosis. Hepatology 2020 Sep 25. https://doi.org/10.1002/hep.31576. [Epub ahead of print]
    1. Chang Y, Ryu S, Kim Y, Cho YK, Sung E, Kim HN, et al. Low levels of alcohol consumption, obesity, and development of fatty liver with and without evidence of advanced fibrosis. Hepatology 2020;71:861-873.
    1. Xu L, Xie J, Chen S, Chen Y, Yang H, Miao M, et al. Light-to-moderate alcohol consumption is associated with increased risk of type 2 diabetes in individuals with nonalcoholic fatty liver disease: a nine-year cohort study. Am J Gastroenterol 2020;115:876-884.
    1. Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393:1597-1608.
    1. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology 2020;71:495-509.